New heart drug goes on PBS
A NEW treatment for heart attack survivors is set to go on the Pharmaceutical Benefits Scheme (PBS) from August 1.
More than 5300 Australians die of repeat heart attacks each year, with deaths expected to increase by more than 40 per cent by 2020.
The oral anti-platelet treatment Brilinta (ticagrelor) will go on to the PBS at a cost to the federal Government of about $100 million over five years.
“We know coronary heart disease remains Australia’s number one killer,” says Professor Philip Aylward, the drug trial’s lead investigator.
“Those fortunate to survive a cardiovascular event remain at increased risk of death from cardiovascular causes once they leave hospital and over time,” he says.